3 Stocks Near 52-Week Highs Worth Selling

Are these three stocks sells or belles? You be the judge!

Mar 6, 2014 at 4:28PM

The beginning of the year swoon has decisively been put in the rearview mirror, with the broad-based S&P 500 launching itself to a new all-time high earlier this week on easing geopolitical fears. For skeptics like me, that's an opportunity to see whether companies have earned their current valuations.

Keep in mind that some companies deserve their current valuations. Dolby Laboratories (NYSE:DLB), for example, has seen its share price rebound nicely since December despite a first-quarter earnings report that lent to modest declines in revenue and adjusted profit. However, investors aren't too concerned with Dolby's past products so much as its bountiful near-field communication patents. NFC technology uses chips to wirelessly communicate payment information between a mobile device and a point-of-sale device. Adoption has been a bit slow, but it's beginning to gain steam, meaning beefed-up royalty payments are likely headed Dolby's way in coming years.

Still, other companies might deserve a kick in the pants. Here's a look at three that could be worth selling.

Is this viable?
We've been hearing for years that fuel-cell technology could alter how we generate electricity, but like all new technologies, the question of whether it's a viable long-term solution has come into question.

Fuel-cell system providers have been on fire over the past couple months, with FuelCell Energy (NASDAQ:FCEL) completing the world's largest fuel-cell park in February, and more recently with Plug Power (NASDAQ:PLUG) vaulting higher after announcing the order of 1,738 fuel-cell systems to power forklifts at Wal-Mart's regional warehouses. That deal was a catalyst that pushed Plug Power into the serious contender category and also moved its share price up more than 4,600% from its 52-week low.

Today, I'm suggesting that it could be time to cash in your chips on FuelCell Energy until we see more consistency in its order history and a dramatic improvement in its bottom line.

FuelCell Energy's losses have shrunk in each year since 2008, which is a start. But the company has not delivered a profitable year, or even positive free cash flow, over the past decade. Based on data from Morningstar, FuelCell Energy has had a free cash outflow of $534 million over the past decade as its shares outstanding have nearly quadrupled in order for the company to raise cash for research and development and ongoing losses.

Don't get me wrong -- I'm not invalidating fuel-cell systems, because Plug Power looks as if it's come out of nowhere to lead the pack. However, there are companies positioned to achieve profitability faster than others, and FuelCell Energy simply isn't one of those companies. With few big-name contracts currently under its belt, I'd suggest now could be the perfect time to head for the exit.

IP-Oh no!
One possibly telltale sign that the IPO market is nearing a top is the ability to throw a dart and essentially make a double-digit gain overnight. Perhaps no sector has exhibited this more than biotech IPOs which have almost uniformly ascended to the heavens. One I'd consider parting ways with is Revance Therapeutics (NASDAQ:RVNC) which has basically doubled from its public offering price of $16 in just one month.

Like most IPOs, Revance is looking to raise cash for additional clinical studies, and it does have some intriguing offerings in its pipeline. Revance's possible claim to fame is a topical version of botulinum toxin, dubbed RT001, which you may know better by its shorthand, Botox. The topical therapy is being tested in an ongoing phase 3 trial as a treatment for crow's feet lines; a phase 2 trial for patients with hyperhidrosis, a condition in which a person sweats excessively; and a phase 2 trial for migraine headaches. The allure, of course, would be the topical Botox application, rather than injection, which has obvious convenience and pain benefits.

However, when I look at Revance I note it has just two products in its pipeline: RT001 as described above, and RT002, an injectable botulinum toxin candidate for the more precise and localized treatment of glabellar lines. While I haven't seen negative data on either its migraine or glabellar lines studies, they're both extremely early trials that probably shouldn't even be counted on by investors yet. This pretty much leaves RT001 as the ultimate derivation of its value.

In my opinion, Revance is going to have to hope that RT001 is everything that investors are making it out to be since the company is likely to burn through $100 million in total cash over the next two years via clinical studies -- every dime it just raised through its IPO. Even if RT001 is eventually approved, we're probably looking at three or more years, by my own estimate, before Revance is cash-flow breakeven. While I'm not throwing Revance in the gutter by any means, I'd say investors' expectations have far outpaced reality at its current price, and it'll soon enough be looking to raise additional cash, possibly resulting in a dilutive share offering.

Lights out
I have actually been an avid supporter of GT Advanced Technologies (NASDAQOTH:GTATQ) for more than a year despite the supplier of solar components temporarily ascending to the top of the Nasdaq's list of stocks with the highest amount of short interest.

The thinking behind short-sellers' pessimism had been that China's solar industry was in such dire straits that GT Advanced Technologies, known also as GTAT, would struggle to survive. Being unprofitable, having a glut of supply on the Chinese market, and having tariffs imposed in select countries, the Chinese solar industry seemed headed toward a bad end.

What turned GTAT and the Chinese solar industry around was a pledge by the Chinese government to install 35 gigawatts worth of solar panels by 2015. With many of the country's domestic solar-providers deep in debt, this was one way of ensuring that they would stay busy and perhaps work their way back to profitability. For GTAT, it also meant a surge in orders, as Chinese solar manufacturers reduced their research and development budgets and essentially threw the onus of innovation on GTAT.

While that has worked wonders for GTAT and caused its share price to explode higher by more than 500% over the trailing 52-week period, GTAT is still unprofitable on a trailing basis and valued at 23 times forward earnings.

Despite strong revenue growth potential, GTAT is in a precarious position in China with the government stepping in to support its solar industry. If solar producers do too well they'll simply go back to R&D on their own and cut back on GTAT's solutions. However, even if they do continue to ramp up orders with GTAT, most Chinese solar providers' balance sheets are loaded with debt, making flexibility and expansion difficult, and likely placing an upside ceiling on production capacity. Furthermore, the Chinese government can't support the solar industry by itself, so things could again get choppy for GTAT beyond 2015.

Similar to Revance, I wouldn't consider throwing GTAT in the gutter, but it just doesn't make sense from a valuation standpoint any longer.

3 stocks you'd be foolish to consider selling
As every savvy investor knows, Warren Buffett didn't make billions by betting on half-baked ideas. He isolated his best few ideas, bet big, and rode them to riches, hardly ever selling. You deserve the same. That's why our CEO, legendary investor Tom Gardner, has permitted us to reveal "The Motley Fool's 3 Stocks to Own Forever." These picks are free today! Just click here now to uncover the three companies we love. 

Sean Williams has no material interest in any companies mentioned in this article. You can follow him on CAPS under the screen name TMFUltraLong, track every pick he makes under the screen name TrackUltraLong, and check him out on Twitter, where he goes by the handle @TMFUltraLong.

The Motley Fool recommends Dolby Laboratories. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

1 Key Step to Get Rich

Our mission at The Motley Fool is to help the world invest better. Whether that’s helping people overcome their fear of stocks all the way to offering clear and successful guidance on complicated-sounding options trades, we can help.

Feb 1, 2016 at 4:54PM

To be perfectly clear, this is not a get-rich action that my Foolish colleagues and I came up with. But we wouldn't argue with the approach.

A 2015 Business Insider article titled, "11 websites to bookmark if you want to get rich" rated The Motley Fool as the #1 place online to get smarter about investing.

"The Motley Fool aims to build a strong investment community, which it does by providing a variety of resources: the website, books, a newspaper column, a radio [show], and [newsletters]," wrote (the clearly insightful and talented) money reporter Kathleen Elkins. "This site has something for every type of investor, from basic lessons for beginners to investing commentary on mutual funds, stock sectors, and value for the more advanced."

Our mission at The Motley Fool is to help the world invest better, so it's nice to receive that kind of recognition. It lets us know we're doing our job.

Whether that's helping the entirely uninitiated overcome their fear of stocks all the way to offering clear and successful guidance on complicated-sounding options trades, we want to provide our readers with a boost to the next step on their journey to financial independence.

Articles and beyond

As Business Insider wrote, there are a number of resources available from the Fool for investors of all levels and styles.

In addition to the dozens of free articles we publish every day on our website, I want to highlight two must-see spots in your tour of fool.com.

For the beginning investor

Investing can seem like a Big Deal to those who have yet to buy their first stock. Many investment professionals try to infuse the conversation with jargon in order to deter individual investors from tackling it on their own (and to justify their often sky-high fees).

But the individual investor can beat the market. The real secret to investing is that it doesn't take tons of money, endless hours, or super-secret formulas that only experts possess.

That's why we created a best-selling guide that walks investors-to-be through everything they need to know to get started. And because we're so dedicated to our mission, we've made that available for free.

If you're just starting out (or want to help out someone who is), go to www.fool.com/beginners, drop in your email address, and you'll be able to instantly access the quick-read guide ... for free.

For the listener

Whether it's on the stationary exercise bike or during my daily commute, I spend a lot of time going nowhere. But I've found a way to make that time benefit me.

The Motley Fool offers five podcasts that I refer to as "binge-worthy financial information."

Motley Fool Money features a team of our analysts discussing the week's top business and investing stories, interviews, and an inside look at the stocks on our radar. It's also featured on several dozen radio stations across the country.

The hosts of Motley Fool Answers challenge the conventional wisdom on life's biggest financial issues to reveal what you really need to know to make smart money moves.

David Gardner, co-founder of The Motley Fool, is among the most respected and trusted sources on investing. And he's the host of Rule Breaker Investing, in which he shares his insights into today's most innovative and disruptive companies ... and how to profit from them.

Market Foolery is our daily look at stocks in the news, as well as the top business and investing stories.

And Industry Focus offers a deeper dive into a specific industry and the stories making headlines. Healthcare, technology, energy, consumer goods, and other industries take turns in the spotlight.

They're all informative, entertaining, and eminently listenable ... and I don't say that simply because the hosts all sit within a Nerf-gun shot of my desk. Rule Breaker Investing and Answers contain timeless advice, so you might want to go back to the beginning with those. The other three take their cues from the market, so you'll want to listen to the most recent first. All are available at www.fool.com/podcasts.

But wait, there's more

The book and the podcasts – both free ... both awesome – also come with an ongoing benefit. If you download the book, or if you enter your email address in the magical box at the podcasts page, you'll get ongoing market coverage sent straight to your inbox.

Investor Insights is valuable and enjoyable coverage of everything from macroeconomic events to investing strategies to our analyst's travels around the world to find the next big thing. Also free.

Get the book. Listen to a podcast. Sign up for Investor Insights. I'm not saying that any of those things will make you rich ... but Business Insider seems to think so.

Compare Brokers